{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:55:20Z","timestamp":1791618920683,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10557-023-07493-6","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T04:02:27Z","timestamp":1694059347000},"page":"97-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the Efficacy of Sacubitril\/Valsartan on Radiofrequency Ablation in Patients with Hypertension and Persistent Atrial Fibrillation"],"prefix":"10.1007","volume":"39","author":[{"given":"Xiaobiao","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erpeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"issue":"9722","key":"7493_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255\u201366.","journal-title":"Lancet"},{"issue":"36","key":"7493_CR2","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","volume":"42","author":"AM Jackson","year":"2021","unstructured":"Jackson AM, Jhund PS, Anand IS, D\u00fcngen HD, Lam CSP, Lefkowitz MP, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42(36):3741\u201352.","journal-title":"Eur Heart J"},{"issue":"2","key":"7493_CR3","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125\u201351.","journal-title":"Circulation"},{"issue":"1","key":"7493_CR4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10840-022-01195-z","volume":"65","author":"S L\u00e9vy","year":"2022","unstructured":"L\u00e9vy S, Steinbeck G, Santini L, Nabauer M, Maceda DP, Kantharia BK, et al. Management of atrial fibrillation: two decades of progress \u2013 a scientific statement from the European Cardiac Arrhythmia Society. J Interv Card Electrophysiol. 2022;65(1):287\u2013326.","journal-title":"J Interv Card Electrophysiol"},{"key":"7493_CR5","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.115.019406","volume":"133","author":"L Di Biase","year":"2016","unstructured":"Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133:1637\u201344.","journal-title":"Circulation"},{"issue":"5","key":"7493_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1707855","volume":"378","author":"NF Marrouche","year":"2018","unstructured":"Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417\u201327.","journal-title":"N Engl J Med"},{"issue":"6","key":"7493_CR7","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s10840-022-01451-2","volume":"66","author":"A Sayed","year":"2023","unstructured":"Sayed A, Awad AK, Abdelfattah OM, Elsayed M, Herzallah K, Marine JE, et al. The impact of catheter ablation in patient\u2019s heart failure and atrial fibrillation: a meta-analysis of randomized clinical trials. J Interv Card Electrophysiol. 2023;66(6):1487\u201397.","journal-title":"J Interv Card Electrophysiol."},{"key":"7493_CR8","doi-asserted-by":"publisher","first-page":"e007731","DOI":"10.1161\/CIRCEP.119.007731","volume":"12","author":"KH Kuck","year":"2019","unstructured":"Kuck KH, Merkely B, Zahn R, Arentz T, Seidl K, Schluter M, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. Circ Arrhythm Electrophysiol. 2019;12:e007731.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"7493_CR9","doi-asserted-by":"publisher","first-page":"870203","DOI":"10.3389\/fcvm.2022.870203","volume":"9","author":"Q Chen","year":"2022","unstructured":"Chen Q, Chen Y, Qin F, Du H, Gan C, Zhou B, et al. Effect of sacubitril-valsartan on restoration and maintenance of sinus rhythm in patients with persistent atrial fibrillation. Front Cardiovasc Med. 2022;9:870203.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"7493_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10557-022-07315-1","volume":"37","author":"Q Wang","year":"2023","unstructured":"Wang Q, Zhuo C, Xia Q, Jiang J, Wu B, Zhou D, et al. Sacubitril\/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation. Cardiovasc Drugs Ther. 2023;37(3):549\u201360.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7493_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40885-020-00141-3","volume":"26","author":"J Liu","year":"2020","unstructured":"Liu J. Highlights of the 2018 Chinese hypertension guidelines. Clin Hypertens. 2020;26:8.","journal-title":"Clin Hypertens"},{"issue":"12","key":"7493_CR12","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/europace\/euv067","volume":"17","author":"JZ Dong","year":"2015","unstructured":"Dong JZ, Sang CH, Yu RH, Long DY, Tang RB, Jiang CX, et al. Prospective randomized comparison between a fixed \u20182C3L\u2019 approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation. Europace. 2015;17(12):1798\u2013806.","journal-title":"Europace"},{"issue":"6","key":"7493_CR13","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137\u201361.","journal-title":"Circulation"},{"issue":"4","key":"7493_CR14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","volume":"63","author":"K Kario","year":"2014","unstructured":"Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698\u2013705.","journal-title":"Hypertension"},{"issue":"3","key":"7493_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","volume":"106","author":"AH Madrid","year":"2002","unstructured":"Madrid AH, Bueno MG, Rebollo JM, Mar\u00edn I, Pe\u00f1a G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106(3):331\u20136.","journal-title":"Circulation"},{"issue":"23","key":"7493_CR16","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.ehj.2003.08.014","volume":"24","author":"KC Ueng","year":"2003","unstructured":"Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24(23):2090\u20138.","journal-title":"Eur Heart J"},{"issue":"1","key":"7493_CR17","doi-asserted-by":"publisher","first-page":"e0263131","DOI":"10.1371\/journal.pone.0263131","volume":"17","author":"X Liu","year":"2022","unstructured":"Liu X, Liu H, Wang L, Zhang L, Xu Q. Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2022;17(1):e0263131.","journal-title":"PLoS One"},{"issue":"1","key":"7493_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12265-021-10137-5","volume":"15","author":"SN Li","year":"2022","unstructured":"Li SN, Zhang JR, Zhou L, Xi H, Li CY, Zhao L. Sacubitril\/valsartan decreases atrial fibrillation susceptibility by inhibiting angiotensin II-induced atrial fibrosis through p-Smad2\/3, p-JNK, and p-p38 signaling pathways. J Cardiovasc Transl Res. 2022;15(1):131\u201342.","journal-title":"J Cardiovasc Transl Res"},{"key":"7493_CR19","doi-asserted-by":"publisher","first-page":"173120","DOI":"10.1016\/j.ejphar.2020.173120","volume":"881","author":"LY Li","year":"2020","unstructured":"Li LY, Lou Q, Liu GZ, Lv JC, Yun FX, Li TK, et al. Sacubitril\/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation. Eur J Pharmacol. 2020;881:173120.","journal-title":"Eur J Pharmacol"},{"key":"7493_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3389\/fphar.2019.01285","volume":"10","author":"Y Suo","year":"2019","unstructured":"Suo Y, Yuan M, Li H, Zhang Y, Li Y, Fu H, et al. Sacubitril\/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice. Front Pharmacol. 2019;10:1285.","journal-title":"Front Pharmacol"},{"issue":"4","key":"7493_CR21","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1002\/ehf2.13937","volume":"9","author":"L Yang","year":"2022","unstructured":"Yang L, Zhang M, Hao Z, Wang N, Zhang M. Sacubitril\/valsartan attenuates atrial structural remodelling in atrial fibrillation patients. ESC Heart Fail. 2022;9(4):2428\u201334.","journal-title":"ESC Heart Fail"},{"issue":"44","key":"7493_CR22","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","volume":"38","author":"RE Schmieder","year":"2017","unstructured":"Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, et al. The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308\u201317.","journal-title":"Eur Heart J"},{"issue":"11","key":"7493_CR23","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","volume":"322","author":"AS Desai","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322(11):1077\u201384.","journal-title":"JAMA"},{"issue":"2","key":"7493_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.14740\/jocmr4076","volume":"12","author":"R De Vecchis","year":"2020","unstructured":"De Vecchis R, Paccone A, Di Maio M. Favorable effects of sacubitril\/valsartan on the peak atrial longitudinal strain in patients with chronic heart failure and a history of one or more episodes of atrial fibrillation: a retrospective cohort study. J Clin Med Res. 2020;12(2):100\u20137.","journal-title":"J Clin Med Res"},{"issue":"4","key":"7493_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3390\/jcm9041111","volume":"9","author":"V Russo","year":"2020","unstructured":"Russo V, Bottino R, Rago A, Papa AA, Liccardo B, Proietti R, et al. The effect of sacubitril\/valsartan on device detected arrhythmias and electrical parameters among dilated cardiomyopathy patients with reduced ejection fraction and implantable cardioverter defibrillator. J Clin Med. 2020;9(4):1111.","journal-title":"J Clin Med"},{"issue":"3","key":"7493_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","volume":"15","author":"C de Diego","year":"2018","unstructured":"de Diego C, Gonz\u00e1lez-Torres L, N\u00fa\u00f1ez JM, Centuri\u00f3nInda R, Martin-Langerwerf DA, Sangio AD, et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 2018;15(3):395\u2013402.","journal-title":"Heart Rhythm"},{"issue":"3","key":"7493_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10840-021-01097-6","volume":"64","author":"J Pan","year":"2022","unstructured":"Pan J, Xu C, Xu B, Lou Y, Wang S, Xing Y. Relationship between the time point of left atrial size change and the outcomes of radiofrequency catheter ablation. J Interv Card Electrophysiol. 2022;64(3):669\u201375.","journal-title":"J Interv Card Electrophysiol"},{"issue":"2","key":"7493_CR28","first-page":"178","volume":"7","author":"S Magnani","year":"2015","unstructured":"Magnani S, Muser D, Chik W, Santangeli P. Adjunct ablation strategies for persistent atrial fibrillation-beyond pulmonary vein isolation. J Thorac Dis. 2015;7(2):178\u201384.","journal-title":"J Thorac Dis"},{"issue":"2","key":"7493_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10840-022-01205-0","volume":"65","author":"O Kreidieh","year":"2022","unstructured":"Kreidieh O, Varley AL, Romero J, Singh D, Silverstein J, Thosani A, et al. Practice patterns of operators participating in the Real-World Experience of Catheter Ablation for Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation (REAL-AF) Registry. J Interv Card Electrophysiol. 2022;65(2):429\u201340.","journal-title":"J Interv Card Electrophysiol"},{"issue":"2","key":"7493_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1161\/CIRCEP.111.966226","volume":"5","author":"S Dixit","year":"2012","unstructured":"Dixit S, Marchlinski FE, Lin D, Callans DJ, Bala R, Riley MP, et al. Randomized ablation strategies for the treatment of persistent atrial fibrillation: RASTA study. Circ Arrhythm Electrophysiol. 2012;5(2):287\u201394.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"3","key":"7493_CR31","first-page":"757","volume":"66","author":"S Wu","year":"2023","unstructured":"Wu S, Li H, Yi S, Yao J, Chen X. Comparing the efficacy of catheter ablation strategies for persistent atrial fibrillation: a Bayesian analysis of randomized controlled trials. J Interv Card Electrophysiol. 2023;66(3):757\u201370.","journal-title":"J Interv Card Electrophysiol"},{"issue":"2","key":"7493_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10840-022-01190-4","volume":"65","author":"W Weng","year":"2022","unstructured":"Weng W, Birnie DH, Ramirez FD, Van Stiphout C, Golian M, Nery PB, et al. Outcomes of a comprehensive strategy during repeat atrial fibrillation ablation. J Interv Card Electrophysiol. 2022;65(2):391\u20139.","journal-title":"J Interv Card Electrophysiol"},{"issue":"1","key":"7493_CR33","doi-asserted-by":"publisher","first-page":"23591","DOI":"10.1038\/s41598-021-02935-3","volume":"11","author":"S Yamashita","year":"2021","unstructured":"Yamashita S, Tokuda M, Mahida S, Sato H, Ikewaki H, Oseto H, et al. Very long term outcome after linear versus electrogram guided ablation for persistent atrial fibrillation. Sci Rep. 2021;11(1):23591.","journal-title":"Sci Rep"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07493-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07493-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07493-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T04:19:01Z","timestamp":1738815541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07493-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7493"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07493-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2738065\/v1","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"20 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Henan Provincial People\u2019s Hospital. The protocol and consent form were approved by the institutional review board of the Henan Provincial People\u2019s Hospital. All patients provided written informed consent for participation before study entry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors reviewed the manuscript and approved its submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}